Celgene Licenses Aprinoia's APN-1607 an Imaging Tracer- for Neurodegenerative Diseases
Shots:
- Celgene to get non-exclusive rights for Aprinoia’s bAPN-1607 and Aprinoia to receive license and usage fee annually
- The focus of the agreement is utilize Aprinoia’s APN-1607 in developing therapies by understanding tau pathology in rare tauopathies including Alzheimer's Disease
- APN-1607 is [18F]-labeled PET imaging tracer- enabling to visualize tau pathology in diverse tauopathies- MCI- dementia due AD- CBS- and PSP and is evaluated in the US- Japan- Taiwan- and China
Ref: Prnewswire | Image: Wsj
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
